A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE)

Simcere

Status and phase: Enrolling; Phase 3

Conditions: Locally Advanced or Metastatic Breast Cancer

Treatments: Drug: SIM0270; Drug: Exemestane tablets; Drug: Fulvestrant injection; Drug: Everolimus (Afinitor®)

Study type: Interventional

Funder types: Industry; Other

Identifiers

NCT06680921

SIM0270-301

Details and patient eligibility

About

This Phase III, randomized, open label, multicenter study will evaluate the efficacy and safety of SIM0270 combined with everolimus compared to physician's choice of treatment in subjects with ER+/HER2- locally advanced or metastatic breast cancer who have had previous treatment with CDK4/6 inhibitor.

Enrollment: 460 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Subjects with histologically or cytologically confirmed ER+/HER2- locally advanced or metastatic breast cancer

2. Subjects must have at least one RECIST 1.1 measurable disease and /or at least 1 lytic or mixed (lytic + sclerotic) bone lesion

3. For women who are post menopausal must meet criteria as defined in the protocol.For women who are premenopausal or perimenopausal and for men: treatment with approved LHRH agonist therapy for screening period and the duration of study treatment

4. Have disease that has demonstrated progression on or after prior treatment:

   1. subjects had received 1 to 2 endocrine therapies in the locally advanced or metastatic setting with disease recurrence/disease progression while being treated with adjuvant endocrine therapy for ≥ 24 months and/or endocrine therapy in the locally advanced or metastatic setting, and derived a clinical benefit from therapy
   2. subjects had received ≤ 1 chemotherapy in the locally advanced or metastatic setting.

5. Eastern Cooperative Oncology Group Performance Status 0-1

6. Adequate organ function

Exclusion criteria

1. Prior treatment with a oral selective estrogen receptor degrader (SERD) or other investigational-ER-directed therapy, or any PI3K-AKI-mTOR inhibitors
2. Treatment with any investigational therapy within 28 days prior to study treatment.Treatment with moderate/strong CYP3A inhibitors or P-gP inhibitor within 14 days prior to first dose or moderate/strong CYP3A inducer within 28 days prior to first dose
3. Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term
4. Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease
5. Active cardiac disease or history of cardiac dysfunction, as defined in the protocol
6. Pregnant or breastfeeding

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

460 participants in 2 patient groups

Experimental group

Experimental group

Description:

SIM0270 to be taken orally as a capsule in combination with Everolimus.

Treatment:

Drug: Everolimus (Afinitor®)

Drug: SIM0270

Control group

Active Comparator group

Description:

Investigator's choice of therapy of either: Fulvestrant alone (a solution for injection), or Everolimus in combination with exemestane, both a tablet to be taken orally.

Treatment:

Drug: Everolimus (Afinitor®)

Drug: Fulvestrant injection

Drug: Exemestane tablets